drugset / Trial / NCT05806853
PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study
NaSingle-groupOpen-labelDiagnostic
Summary
The overall goal is to provide an innovative approach to restage patients with biochemical recurrence of prostate cancer by using hybrid PET/MR with innovative radiotracers (68Ga-PSMA and 68Ga-RM2)
Timeline
- Start
- 2020-06-03
- Primary completion
- 2022-10-05
- Completion
- 2022-10-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | 160 mbq | Intravenous |
| Subject | 68Ga-RM2 | Diagnostic / imaging agent | 140 mbq | Intravenous |